Responses to parliamentary questions
Question from Deputy Ken O’Flynn - PQ 39840-26
Deputy O'Flynn asked about the reimbursement of omaveloxolone (Skyclarys). Read the HSE response.
From: Communications and public affairs
Published: May 2026
Updated: July 2026
Documents
Question from Deputy Ken O’Flynn - PQ 39840-26
PDF, 230KB, 3 pages
Summary
To ask the Minister for Health whether the HSE Drugs Group considered the progressive and degenerative nature of Friedreich's ataxia, including irreversible disease progression during reimbursement delays, in its consideration of omaveloxolone (Skyclarys); and if she will make a statement on the matter.
This is a beta version - your feedback will help us to improve it